Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bleeding Disorder Clear all
Completed Phase 2Phase 3 Interventional

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

NCT05070260
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous glenzocimab (ACT017) 1000 mg, Intravenous Placebo
Drug
Lead sponsor
Acticor Biotech
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Bradenton, Florida • St. Petersburg, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 3:40 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

NCT05245227
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Sublingual Misoprostol, IV Oxytocin
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 21, 2026, 3:40 AM EDT
Recruiting Not applicable Interventional

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NCT06957366
View directory record Official record
Conditions
Atrial Fibrillation (AF), VTE
Interventions
PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 21, 2026, 3:40 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine hydrochloride, Preservative-free normal saline
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Assess the Feasibility and Tolerability of the AccuFlow Perfusion Sensor for Intrapartum Hemorrhage

NCT04370639
View directory record Official record
Conditions
Hemorrhage, Postpartum, Hemorrhage, Vasoconstriction
Interventions
AccuFlow sensor, Survey
Device · Other
Lead sponsor
Megan Lord
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323
View directory record Official record
Conditions
Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Up to 5 Years · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954
View directory record Official record
Conditions
Primary Immunodeficiency, Common Variable Hypogammaglobulinemia, X-linked Hypogammaglobulinemia, Hypogammaglobulinemia, Immunodeficiency With Hyper-IgM, Wiskott-Aldrich Syndrome
Interventions
Gammaplex (Intravenous immunoglobulin)
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
3 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 21, 2026, 3:40 AM EDT
Completed No phase listed Observational

Serum Procalcitonin

NCT00954551
View directory record Official record
Conditions
Subarachnoid Hemorrhage (SAH)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 21, 2026, 3:40 AM EDT
Withdrawn Phase 4 Interventional

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

NCT04690322
View directory record Official record
Conditions
Hemophilia A, Factor VIII
Interventions
Eloctate, Adynovate, Emicizumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Recruiting Not applicable Interventional

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

NCT06347796
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Conventional Surgery, Middle Meningeal Artery Embolization (MMAE)
Procedure · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 90 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Not applicable Interventional

Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) "I-InTERACT

NCT01056146
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Internet-based Interacting Together Everyday: Recovery After Childhood TBI, Internet Resources Comparison
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 9 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population

NCT03404375
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Gauss Triton system
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Oct 21, 2026, 3:40 AM EDT
Completed No phase listed Observational

Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer

NCT00339651
View directory record Official record
Conditions
Endometrial Hyperplasia, Endometrial Cancer, Postmenopausal Bleeding, Vaginal Bleeding
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 120 Years · Female only
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Hillsboro, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 21, 2026, 3:40 AM EDT
Withdrawn Not applicable Interventional

Attention Intervention Management

NCT01779427
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed
Interventions
AIM
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 21, 2026, 3:40 AM EDT
Completed No phase listed Observational

Thromboelastometry Prediction Utility for Risk of Abortion

NCT03548701
View directory record Official record
Conditions
Pregnancy Trimester, First, Abortion, Threatened
Interventions
Thromboelastometry testing
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 21, 2026, 3:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BVA-200 vs BVA-100 Validation Study

NCT06227819
View directory record Official record
Conditions
Heart Failure, High Blood Pressure, High Cholesterol, Anemia, Diabetes, Thyroid Diseases, Kidney Diseases, Clotting Disorder, Trauma, Other Disease
Interventions
BVA-200
Diagnostic Test
Lead sponsor
Daxor Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 21, 2026, 3:40 AM EDT
Completed No phase listed Observational

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

NCT01970930
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
Blood specimen
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 21, 2026, 3:40 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage

NCT00593268
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 3:40 AM EDT
Withdrawn Phase 4 Interventional

Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study

NCT01935908
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

A Study Investigating Treatment Factor X in People With Factor X Deficiency

NCT00930176
View directory record Official record
Conditions
Factor X Deficiency
Interventions
Human Coagulation FACTOR X
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
San Francisco, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 1 Interventional

Remote Ischemic Preconditioning in Subarachnoid Hemorrhage

NCT01158508
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Subarachnoid Hemorrhage, Cerebral Vasospasm, Intracranial Aneurysm
Interventions
Remote ischemic preconditioning
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 21, 2026, 3:40 AM EDT
Completed Phase 3 Interventional Results available

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

NCT02615691
View directory record Official record
Conditions
Hemophilia A
Interventions
PEGylated Recombinant Factor VIII, ITI
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 21, 2026, 3:40 AM EDT